NOVEMBER 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA November 27. Sugemalimab – NSCLC EGFR/ALK/ROS1. The European Commission (EC) has approved the extension of indication for the anti-PD-L1 monoclonal antibody to include the treatment of unresectable stage III non‑small‑cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose disease has not progressed following concurrent or […]